JMJill A. Meyer

Jill A. Meyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jill A. Meyer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda A. Bedwell

    Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA

    1 shared publication
  • Andrew R. Marks

    Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

    1 shared publication
  • Haikel Dridi

    Columbia University

    1 shared publication
  • Jonathan S. Peters

    Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA

    1 shared publication
  • Kaylee Wedderburn-Pugh

    Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

    1 shared publication
  • Khalid Said Mohammad

    Department of Anatomy, College of Medicine, Alfaisal University

    1 shared publication

Latest Publications

  • Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice

    by Yang Liu, Steven Reiken, Haikel Dridi, Qi Yuan, Khalid S. Mohammad, Trupti Trivedi, Marco C. Miotto, Kaylee Wedderburn-Pugh, Leah Sittenfeld, Ynez Kerley, et al.

    Chemotherapy-induced cognitive dysfunction (chemobrain) is an important adverse sequela of chemotherapy. Chemobrain has been identified by the National Cancer Institute as a poorly understood problem for which current management or treatment strategies are limited or ineffective. Here, we show that chemotherapy treatment with doxorubicin (DOX) in a breast cancer mouse model induced protein kinase A (PKA) phosphorylation of the neuronal ryanodine receptor/calcium (Ca2+) channel type 2 (RyR2), RyR2 oxidation, RyR2 nitrosylation, RyR2 calstabin2 depletion, and subsequent RyR2 Ca2+leakiness. Chemotherapy was furthermore associated with abnormalities in brain glucose metabolism and neurocognitive dysfunction in breast cancer mice. RyR2 leakiness and cognitive dysfunction could be ameliorated by treatment with a small molecule Rycal drug (S107). Chemobrain was also found in noncancer mice treated with DOX or methotrexate and 5-fluorouracil and could be prevented by treatment with S107. Genetic ablation of the RyR2 PKA phosphorylation site (RyR2-S2808A) also prevented the development of chemobrain. Chemotherapy increased brain concentrations of the tumor necrosis factor–α and transforming growth factor–β signaling, suggesting that increased inflammatory signaling might contribute to oxidation-driven biochemical remodeling of RyR2. Proteomics and Gene Ontology analysis indicated that the signaling downstream of chemotherapy-induced leaky RyR2 was linked to the dysregulation of synaptic structure–associated proteins that are involved in neurotransmission. Together, our study points to neuronal Ca2+dyshomeostasis via leaky RyR2 channels as a potential mechanism contributing to chemobrain, warranting further translational studies.